Genmab — Juni 2017
-
Sklerosemiddel fra Roche reducerer risiko for handicap
Nye resultater fra Roches studier med sklerosemidlet Ocrevus viser positive effekter på patienter, og reducerer risikoen for at blive bundet til en kørestol.
(medwatch.dk)
-
-
Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS
(brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma -http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=2282975
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind

